Home › Interim Results from Phase 1b/2 Study Evaluating the Combination of Mercks KEYTRUDA (pembrolizumab) and Eisais HALAVEN (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS
 

Keywords :   


Interim Results from Phase 1b/2 Study Evaluating the Combination of Mercks KEYTRUDA (pembrolizumab) and Eisais HALAVEN (eribulin mesylate) Injection in Metastatic Triple-Negative Breast Cancer Presented at 2016 SABCS

2016-12-12 13:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. & WOODCLIFF LAKE, N.J. KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new interim data investigating Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with Eisais microtubule dynamics inhibitor, HALAVEN (eribulin), in patients with metastatic triple-negative breast cancer (TNBC). Language: English Contact: Media:MerckPamela Eisele, 267-305-3558orKim Hamilton, (908) 740-1863orEisai Inc.Laurie Landau, 201-746-2510orInvestors:MerckTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898orEisai Inc.Ivor Macleod, 201-746-2660 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: results study presented combination

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04JLR to Use Alkegens EV Battery Solutions
29.04Albany International Ceases Manufacturing in South Korea
29.04Summertone Bronzing Gel Is New from Goop
29.04Ahlstrom Announces New Divisional Structure
29.04Vinted makes first profit on used fashion
29.04USDA issues March Cold Storage report
29.04US probes Ford hands-free driving tech after crashes
29.04ABG launches new Vectra AutoSet turret rewinder
More »